Injectables On The Rise: Meeting Global Pharma Demands
The global pharmaceutical industry is experiencing a pronounced shift toward injectable drug formulations. This trend is fueled by the growing need for rapid, reliable, and effective treatments for a range of acute and chronic conditions. As more pharmaceutical companies seek to expand their portfolios with injectable products, the demand for high-quality, scalable manufacturing solutions has never been greater.
The Surging Demand for Injectable Drugs
Injectable drugs are increasingly favored for their ability to deliver medication directly into the bloodstream, ensuring fast onset of action and high bioavailability. This is especially critical for patients who require immediate therapeutic intervention or those for whom oral administration is not feasible. The market for parenteral injectables is projected to reach $150.65 billion by 2028, propelled by the rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and infections, as well as the need for rapid response therapies.
Moreover, the aging global population and the expansion of healthcare access are amplifying demand for reliable injectable solutions. As a result, pharmaceutical companies are under pressure to accelerate production, reduce time-to-market, and ensure consistent quality—all while navigating increasingly complex regulatory requirements.
Akums’ State-of-the-Art Injectable Manufacturing
Recognizing these industry trends, Akums has made significant investments in expanding its sterile manufacturing capabilities. The company recently announced the operationalization of a new facility dedicated to producing lyophilized injectables, vials, ampoules, eye and ear drops, and form-fill-seal (FFS) products. Lyophilization is a specialized process that removes water from sensitive pharmaceutical compounds at freezing temperatures, preserving their stability and extending shelf life. This technology is particularly valuable for drugs that are sensitive to heat or moisture, enabling global distribution and long-term storage.
Akums’ facility is designed to support large-scale manufacturing across a wide range of therapeutic areas, addressing the growing need for specialized injectable products. With an annual production capacity of 767 million units, it is well-positioned to address the increasing global demand for high-quality, specialized injectable products
Regulatory Excellence and Quality Assurance
Manufacturing injectables is among the most complex and highly regulated processes in the pharmaceutical industry. It requires a controlled environment, specialized expertise, and rigorous quality standards to ensure patient safety. Akums adheres to stringent global standards such as EU GMP, WHO GMP, and other international guidelines, ensuring that every batch meets the highest levels of safety, efficacy, and consistency.
The company employs advanced aseptic processing techniques, including sterile filtration and precision filling, to minimize contamination risks and maintain product integrity. Akums’ robust pharmacovigilance and quality assurance systems further reinforce its reputation as a reliable partner for pharmaceutical companies seeking to bring injectable products to market quickly and confidently.
Supporting Pharma Companies Worldwide
Akums partners with over 1500 pharmaceutical and healthcare companies, offering tailored solutions that enable rapid market entry and scalability. Its expertise spans formulation development, process optimization, regulatory affairs, and commercial-scale production. Whether supporting niche projects or large-scale global supply contracts, Akums’ scalable infrastructure and regulatory excellence empower its clients to meet rising demand and navigate complex market dynamics.
Innovations in Drug Delivery and Patient-Centric Solutions
The injectable drug landscape is evolving, with a greater emphasis on patient-centric treatment and innovative delivery systems. Contemporary drug design now focuses not only on safety and efficacy but also on improving dose compliance and ease of administration. Akums is at the forefront of this shift, investing in advanced technologies and processes that enable the development of user-friendly, precise, and reliable injectable products.
As the demand for injectable drugs continues to rise, pharmaceutical companies require partners who can deliver not only capacity but also uncompromising quality and regulatory expertise. Akums’ investment in advanced sterile manufacturing, commitment to regulatory compliance, and scalable production capabilities make it a preferred partner for pharmaceutical companies worldwide. By leveraging its cutting-edge facilities and deep industry knowledge, Akums is helping to meet the global demand for high-quality injectable solutions, ensuring better health outcomes for patients everywhere.
With a team of 400+ R&D scientists, Akums has developed over 220+ innovative products, delivering excellence across diverse and complex dosage forms. From Tablet-in-Tablet, Inlay Tablets, and Mouth-Melt Powders to Sustained Release Syrups and Ready-to-Use Antibiotic Syrups — innovation is at the core of Akums strategy.
news